Uso de células CAR-T no tratamento de doenças onco-hematológicas

Abstract

Onco-hematologic diseases are disorders that impact the blood, bone marrow, and lymphatic organs, resulting in abnormal proliferation of blood cells and a decrease in the production of healthy cells, including conditions such as leukemia, lymphoma, myeloma, and aplastic anemia. CAR-T cell immunotherapy can be considered a crucial approach to treating these pathologies, involving the genetic modification of patient T cells to specifically target cancer cells. This integrative literature review, conducted through platforms such as PubMed, Virtual Health Library (ScieELO, EBSCO, DynaMed), Google Scholar, national and international journal articles, theses, dissertations, epidemiological data collection, and reviews, aims to elucidate the function of CAR-T cells and their effectiveness in patients' organisms. The ability of these modified cells to recognize and attack cancer cells significantly increases treatment response rates, offering a promising perspective for patients with onco-hematologic diseases. Despite being a recent treatment with potential complications, CAR-T cell immunotherapy proves to be substantial and highly effective in treating individuals affected by onco-hematologic diseases. This work seeks to disseminate information about this innovative therapy to the population, highlighting its benefits, even in the face of potential challenges.